RECCE 111
Alternative Names: R-111; RECCE-111Latest Information Update: 12 Feb 2024
At a glance
- Originator Recce Pharmaceuticals
- Class Antibacterials
- Mechanism of Action Bacterial protein inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Streptococcal infections
Most Recent Events
- 07 Feb 2024 Recce Pharmaceuticals signs a Memorandum of Understanding (MoU) with PT Etana Biotechnologies Indonesia for the clinical development of RECCE 111 in Indonesia
- 01 Apr 2021 Preclinical trials in Streptococcal infections in Australia (IV) before April 2021
- 01 Apr 2021 Positive preclinical pharmacodynamics data in Streptococcal infections released by Recce Pharmaceuticals